Preclinical data from experimental models and human observations confirmed high BLyS concentrations in lupus prone mice and approximately half of human lupus patients; BLyS antagonism ameliorated disease symptoms and survival in animal models [28]. This evidence concerns the gene TNFSF13B and systemic lupus erythematosus.